

Target Validierung: Nicht-gelbasierte Proteomforschung zur systematischen und quantitativen Peptidanalyse

DPhG – Mainz, 6.Oktober 2005

Lothar Jänsch





Organisation of Host-Pathogen Interaction Studies

Cell Biology Prof. Jürgen Wehland



Affymetrix platform

Prof. Jan Buer



Proteome Research Group



Identi. & Characterisation of bacterial virulence factors

Structural Biology

Prof. Dirk Heinz



Mouse facility Dr. Lengeling / Dr. Müller





Listeria monocytogenes



- Gram-positive bacterium
- Facultative intracellular human pathogen
- Capacity to overcome three cellular barriers: intestinal-, brain-blood- and the placental barrier
- Genome published, *L. innocua & L. monocytogenes* (Glaser et al.,2001)

Picture taken from: J. A. Vazquez-Boland et al., Clin Microbiol Rev 14 (3):584-640, 2001



Host-Pathogen Interaction: Listeria monocytogenes





Host-Pathogen Interaction Studies





Comparison of HGF and InIB mediated host cell signalling



Rosario et al., Trends Cell Biol. 2003 Jun;13(6):328-35, modified



Signal transduction of the infected host upon interaction with pathogens

L. monocytogenes	InIB	cMet	Invasion
L. monocytogenes	InIA	E-Cadherin	Invasion
Y. enterolytica	Invasin	Integrin	Invasion
H. pylorii	CagA	Src	Persistence
P. aeruginosa	?	EGFR	Invasion
P. aeruginosa	ExoS	Ras/Raf	Cyto-toxicity

Further bacterial effectors / receptors have to be identified

or

We still have severe limitations in our knowledge about fundamental cellular signaling pathways



Aim & Strategy (started 2003)

Aim:

- 1) Define an experimental strategy for the functional analysis of receptor mediated signalling
- 2) Compare HGF and Internalin B induced epithelial cells to understand the level of "molecular mimicry"

Strategy:



Cell lysis

Igepal, Phosphatase-/Protease-Inhibitors

"Proteomics"



Host cell response analysis: Expression and Phosphoproteome analysis on traditional 2D-PAGE

pl



- Induction of HeLa S3 cells
- Lyse the cells after 30min (1% Igepal, Na₃V0₄, NaF)
- RuBPS-stain (green) for expression analysis
- ProQ-stain (red) for detection of phosphorylated proteins

Several differentially phosphorylated proteins can be detected



2D-PAGE vs. LC-MS/MS





Peptide-Sequencing





Frequency and suppressed ionization behavior of phosphorylated peptides in complex samples





LC-MS/MS for the characterization of phosphorylated peptides

Prerequisites:

- 1. Specific enrichment of phosphorylated peptides.
- 2. Systematic access on kinases.

Preferable:

3. Relative and absolute quantification of single peptides.



1. Specific enrichment of phosphorylated peptides



(1.) IMAC (Immobilized Metall Affinity Purification)

- Methylation of acidic amino acids
- Binding of phosphorylated peptides to immobilized Ga²⁺
- Washing
- Elution
- Characterization by LC-MS/MS



Ficarro et al., 2002: Systematic identification of phosphorylated peptides from S. cereviseae.



Systematic identification of phosphorylated peptides

- 1. Enrichment of phosphorylated peptides based on IMAC (Immobilized Metal Affinity Chromatographie, Ficarro et al., 2002)
- 2. Protein identification **and** phosphosite determination by LC-MS/MS.

ID	Phosphosite Phosphol	base Scansite
	S139	Cdk5_Kin // Cdc2_Kin
	S287	
ail1597477	S352	
gij 1567477	S812	
	S1133	
	S1134	
	T399	
	T401	
gi 2498954	S405	GSK3_Kin // Erk1_Kin
	S417	
	S418	
	S22 cdc2	Cdc2_Kin // Erk1_Kin
ail24000	S390	
91/34220	S392 cdc2	
	S403 pkc	
	S280	
ail107092	T354	
gi[107082	S358	
	T521	
	S58	Casn_Kin2
	S61	Casn_Kin2
ail12232387	S73	
	ID gi 1587477 gi 2498954 gi 34228 gi 107082	ID Phosphosite Phosphol S139 S287 S352 S352 S812 S1133 S1133 S1134 S1134 gi 2498954 S405 S417 gi 34228 S390 S392 cdc2 gi 34228 S390 S392 cdc2 gi 107082 S280 S280 S358 T354 S358 S58 S61 gi 12232387 S73 S73 S73

1D-LC-MS/MS (2004):

- Identification of 112 phosphorylated proteins
- 189 phosphosites
- known and unknown sites

Purification efficiency of phosphopeptide

> 94 %



Systematic evaluation of posttranslational modification: Phosphosite Report





2. Systematic access on kinases



Affinity Purification of Protein Kinases

Several small molecule kinase inhibitors exhibited a low substrate specificity

Immobilized inhibitor:	No. fished Kinases
Purvalanol	64
Pyridopyrimidine	61
Iressa	25
Imidoimidazol	23
BisindolyImaleimides	11
Tarceva	10
SU 6668	9

A total of: 127 Protein Kinases (25% of the human kinome)



Mapping of Protein Kinases by affinity chromatography based on small kinase inhibitors

SCIENCE Mascot Search Results

User Funcil	: Mascot D	emon
Search title	FileName: /f	a names, FileTout, Afile touts, Sample Group, Asample groups, Maar, Amers
Mg data file	117iherry24\c	te name/, filelext. <file_text ,="" <="" <sample="" <use="" bel.="" bloup.="" gloup="" sample="" td=""></file_text>
MS uata life :	Vainstv34 (C	MUNILE-MS_UI(PKI_DACETENIIIIA) VALIAIELUNG(20003_1_1_1_1.PKI
Tavanase :	Mammalia (ma	(10005) sequences; 0/14520/ festudes;
Taxonomy .		nals) (Jouls sequences) 10.90.26 mm
Cimificant bita		(M11240) Expression exertain binner (CV /EC 2.7.1.112) (C. CDC binner) (Detain tempsion binner (VI))
significant nits.	CONS HOMAN	$(P_{1}(24))$ represent the protein kinase (SK (E(2.7.1.112)) (C-SK kinase) (Fittell-(growthe kinase (E)))
	CDK2 DOMAN	(P24941) (eff division protein kinase 2 (E(2,7,1,3)) (p3) protein kinase) (063600) (eff division protein kinase 2 (E(2,7,1,3))
	DDYK HIDOM	(000764) Burgidoval kinage (FC 2 7 1 25) (Burgidovine kinage)
	CDC2 HIDOM	(000704) Fyllockal Alasse (b. 2.7.1.33) (Fyllockale Alasse) ($PO(602)$ (all division control protein 2 homolog (FC 2.7.1.27) (n24 protein binace) (Crolin-dependence)
	MK01 MOUSE	(P6395) Citagenestivated protein kinge 1 (FC 2 7 1 37) (Fytracellular signal-regulated kinge
	MK03 HIMAN	(P27361) Mitogen-activated protein kinase 3 (FC 2 7 1 37) (Extracellular signal regulated kinase 1)
	KS6a1 HIMAN	(115418) Bibosomal protein S6 kinase aluba 1 (FC 2 7 1 37) (S6K-aluba 1) (90 kha ribosomal protein
	KS6A3 HIMAN	(P51812) Ribosomal protein S6 kinase aluba 3 (EC 2.7.1.37) (S6K-aluba 3) (90 kDa ribosomal protein
	CDK6 HUMAN	(000534) Cell division protein kinase 6 (EC 2.7.1.37) (Serine/threenine-protein kinase PLSTIRE)
	KCIA HUMAN	(P48729) Casein kinase I, alpha isoform (EC 2.7.1) (CKI-alpha) (CK1)
	LCK HUMAN	(P06239) Proto-oncogene tyrosine-protein kinase LCK (EC 2.7.1.112) (P56-LCK) (LSK) (T cell-specific
	KCC2G HUMAN	(013555) Calcium/calmodulin-dependent protein kinase type II gamma chain (EC 2.7.1.123) (CaM-kinase
	CDK5 BOVIN	(Q02399) Cell division protein kinase 5 (EC 2.7.1.37) (Tau protein kinase II catalytic subunit) (TP
	AAKG1 HUMAN	(P54619) 5'-AMP-activated protein kinase, gamma-1 subunit (AMPK gamma-1 chain) (AMPKg)
	AAKG1 BOVIN	(P58108) 5'-AMP-activated protein <mark>kinase</mark> , gamma-1 subunit (AMPK gamma-1 chain) (AMPKg)
	KS6A2 HUMAN	(Q15349) Ribosomal protein S6 <mark>kinase</mark> alpha 2 (EC 2.7.1.37) (S6K-alpha 2) (90 kDa ribosomal protein
	MKO9 HUMAN	(P45984) Mitogen-activated protein <mark>kinase</mark> 9 (EC 2.7.1.37) (Stress-activated protein <mark>kinase</mark> JNK2) (c
	KCC4 HUMAN	(Q16566) Calcium/calmodulin-dependent protein <mark>kinase</mark> type IV (EC 2.7.1.123) (CAM <mark>kinase</mark> -GR) (CaMK I
	PAK4 HUMAN	(096013) Serine/threonine-protein <mark>kinase</mark> PAK 4 (EC 2.7.1.37) (p21-activated <mark>kinase</mark> 4) (PAK-4)
	KCID HUMAN	(P48730) Casein <mark>kinase</mark> I, delta isoform (EC 2.7.1) (CKI-delta) (CKId)
	M4K1 HUMAN	(Q92918) Mitogen-activated protein <mark>kinase kinase kinase</mark> kinase 1 (EC 2.7.1.37) (MAPK/ERK kinase kin
	MP2K2 HUMAN	(P36507) Dual specificity mitogen-activated protein <mark>kinase</mark> kinase 2 (EC 2.7.1) (MAP <mark>kinase</mark> kinase
	STK6 HUMAN	(014965) Serine/threonine-protein kinase 6 (EC 2.7.1.37) (Serine/threonine kinase 15) (Aurora/IPL1-
	MP2K1 CRIGR	(Q63980) Dual specificity mitogen-activated protein kinase kinase 1 (EC 2.7.1) (MAP kinase kinase
	NEK9 HUMAN	(Q8TD19) Serine/threenine-protein kinase Nek9 (EC 2.7.1.37) (NimA-related protein kinase 9) (Nercol
	GSK3B HUMAN	(P49841) Glycogen synthase kinase-3 beta (EC 2.7.1.37) (GSK-3 beta)
	KCIGI HUMAN	(09HCPU) Casein kinase I, gamma I isoform (EC 2.7.1) (CKI-gamma I)
	AAPKI HUMAN	(Q13131) 5'-AMP-activated protein kinase, catalytic alpha-1 chain (EC 2.7.1) (AMPK alpha-1 chain)
	HCK MACFA	(093030) Tyrosine-protein kinase HCK (EC 2.7.1.112) (p50-HCK) (Hemopoletic cell kinase)
	MPZKZ MUUSE	(103332) Juai specificity mitogen-activated protein kinase kinase 2 (EC 2.1.1) (MAP kinase kinase
	CDK9 HUMAN	(PSU/30) tell division protein kinase 9 (EC 2.7.1.37) (Cyclin-dependent kinase 9) (Serine/threonine (09/379) 51 Mm setivated waterin kinase 1 exhunt (20/074 het 1 exhunt (20/074) bit 1 exhut (20/074) bit 1 exhunt (20/074) bit 1 exhut (20/074)
	CDV7 NDCAN	(191470) J - AMF - activated pictern Kindse, betari subunit (AMFK betari Chain) (AMFKb) (195012) (all division protein kinger 7 (PC 2 7 1 27) (CDV activating kinger) (CDV) (TETTV basal tr
	KDCT HIDOM	(10013) CELL different sinase ($E(2,7,1,3)$) (DK-activating sinase) (CAR) (IELL Basal (E(0013)) (DK-activating sinase) (CAR) (IELL Basal (E(2,7,1,3)))
	SRC MOUSE	($P(0,510)$, $P(0$
	GAK HIMAN	(014976) Cyclin Grassociated kinase (EC 2.7.1)
	CCNB1 HIMAN	(P14635) 62/mitotic-specific cyclin B1
	SRC HUMAN	(P12931) Proto-oncogene tyrosine-protein kinase Src (EC 2.7.1.112) (p60-Src) (c-Src)
	MAT1 HUMAN	(P51948) CDK-activating kinase assembly factor MAT1 (RING finger protein MAT1) (Menage a trois) (CD



3. Relative and absolute quantification of single peptides.





GBF







Quantification of Peptides by iTRAQ[™]





Relative quantification of phosphorylated peptides





iTRAQ link peptide sequencing (MS/MS) with the process of relative phosphopeptide quantification





Cortactin: Regulation of a Erk1 dependent phosphosite after InIB and HGF induction



T401/S405 phosphorylation:



total phosphorylation:



Martinez-Quiles et al., Molecular and Cellular Biology, 2004



Dynamic of quantification signals

Reporter intensities the iTRAQ channels 114.1 & 115.1 Da



Most intense reporters are:

- Tryptic peptides ending on K (harboring two labels)
- Short peptides (due to ion suppression in longer peptides)
- has to be specified...



Deviation of regulatory data





Quantification of kinase fractions by iTRAQ

	A B	С	D	E	F	G	Н		J	K	L	M	N	Bearbeitungsleiste
1		ITR/		PORT										
2														
3														
4														
5														
								INTENSITY	INTENSITY					
C UIT	1000	DESCE	DEDTID	SEQUENCE	SCOPE	DANK	CHARGE	114	117	RECULATION				
	ACC	DESCR	FEFID	SEQUENCE	SCORE	KAINK	CHARGE	114	117	REGULATION				
0			L Turopino pr	Latein kinaaa CSK (EC 3 7 1 113) (C S	PC kinooo)	∠⊡rotoin tu	l Irocino kinoco							
a	I Cok_h	1010 (F41240)	Tyrosine-pro	LL OTICK	RC Kinasej	1		1203	1136	1.06				
10			<u>96</u>	GSLVDYLR	39	1	2	1175	1130	1.00				
11			124	VSDEGLTK	62	1	2	4287	3913	1.00			-	
12			257	GEEGDVMLGDYR	35	1	2	198	146	1.36				
13			264	EGIIPANYVQK	52	1	2	275	252	1.09				
14			310	LLYPPETGLFLVR	51	1	2	2839	2916	0.97				
15			311	LLYPPETGLFLVR	53	1	3	180	159	1.13				
16			387	HSNLVQLLGVIVEEK	61	1	3	88	86	1.02				
17			428	NDATAQAFLAEASVMTQLR	81	1	3	32	34	0.93				
18			<u>450</u>	GDVLTIVAVTKDPNWYK	35	1	3	63	58	1.08				
19			<u>475</u>	FSLDVCEAMEYLEGNNFVHR	74	1	3	84	92	0.92				
20			<u>480</u>	FSLDVCEAMEYLEGNNFVHR	56	1	3	67	57	1.17				
21			<u>515</u>	LSIDEEVYFENLMQLVEHYTSDADG	47	1	3	2	2	1			AVERAG	E STDEVP
22													1.07	0.11
23										sum:	10493	9995	1.05	0.95
24	2 MKU1_	HUI (P28482)	Mitogen-act	ivated protein kinase 1 (EC 2.7.1.37)	(Extracellu	lar signal-re	gulated kinas	se 2)	0.10	1.00				1
25			103		39	4	2	87.3	048	1.05				
20			134		50	1	2	4090	4470	1.1			-	
2/			514		22	1	2	1170	210	1.03				
20			301		17	1	2	1359	1224	1.11	-			
30			302		54	1	2	1770	1654	1.07				
31			413		56	1	2	233	262	0.89			+	
32			414		78	1	2	200	202	0.00			-	
33			498	YTNLSYIGEGAYGMVCSAYDNVNK	77	1	ã	164	232	0.71			-	
34			500	YTNLSYIGEGAYGMVCSAYDNVNK	61	1	3	24	46	0.53				
35			505	APTIEQMKDVYIVQDLMETDLYK	52	1	3	199	213	0.93				
36			506	APTIEQMKDVYIVQDLMETDLYK	38	1	4	81	86	0.95			AVERAG	E STDEVP
37													0.94	0.17
38										sum:	11260	10648	1.06	0.95
39	3 PDXK_	HUI (000764)	Pyridoxal k	inase (EC 2.7.1.35) (Pyridoxine kinas	e)									
40			154	NPAGSVVMER	36	1	2	629	583	1.08				
41			256	KIHSQEEALR	50	1	3	530	510	1.04				
42			315	DIEDPEIVVQATVL	38	1	2	30	51	0.58			-	
43			409	GQVLNSDELQELYEGLR	95	1	2	80	106	0.75				
44			440	DKSFLAMVVDIVQELK	41	1	3	4	1212					
45		_	442	DKSFLAMVVDIVQELK	42	1	3	70	75	0.93			_	
46	U ITHOR D	out / shouth	(464)		48	1	2	269	312	0.86			1	
14.4.3	M (Irray-Ret		sport ¿ par	anneport /				18		100				
Bereit	_							-						NF
📲 Sta	art 🕱	🗕 🖸 🐼	🧷 🔡 Pa	lm Desktop 🛛 🙀 Itraq - Inbox f	for Ija@	Microso	ft PowerPoint	Microsoft	Excel - 114			0 80 1	9 😼 🍪 🥸	- 18 🕥 (L_ 09:44



Deviation of regulatory data (*



* : Data certainly contain false-positive reporter signals and final deviations will be significantly lower in well defined workflows



Characterization of quantification signals

iTRAQ reagent 114:



Mass delta of the reporter masses also depend on their intensities

Maximum mass delta of \pm 0.01 Da has to be considered



Specificity of the reporter channels 114.1, 115.1, 116.1 and 117.1 Da

PTM by Ornithyl: Monoisotopic Mass Change:114.079

AATPQPVTMFR Alanine **a-ion** = 115,09 Da

Proline at the C-terminus of the protein (Lmo1388) **y-ion** =116.063 Da

C-terminus Asparatic Acid z-ion = 117.04 Da

Amide of Valine y-ion = 117.09 Da





Specificity of the reporter channels (only 117.1 Da reagent used)

SEQUENCE	SCORE	RANK	CHARGE	INTENSITY 114.1	INTENSITY 115.1	INTENSITY 116.1	INTENSITY 117.1	MASS 114.1	MASS 115.1	MASS 116.1	MASS 117.1	
TVLGK	18.29	1	2	0	0	13.4	595 G	0.00	0.00	116.09	117 10	
LTELK	17.02	1	2	n n	ñ	37.17	1418	0.00	0.00	116.00	117.10	
AGYTEK	24.49	1	2	ñ	ñ	16.33	4437	0.00	0.00	116.10	117.10	
GWYDAK	20.66	1	2	n n	ň	0	59 14	0.00	0.00	0.00	117.10	
EGYTEK	15.19	1	2	2.141	ŏ	16.21	407.2	114.11	0.00	116.10	117.10	
LDISSNK	42.68	1	2	0	ñ	91.22	1848	0.00	0.00	116.10	117 10	
GWYDEK	16.16	1	2	Ō	Ő	0	16.15	0.00	0.00	0.00	117.11	
WDFATSK	37.72	1	2	Ō	2.104	10.38	207.7	7 0.00	115.10	116.11	117.10	
WDFATDK	38.2	1	2	Ō	0	9,193	455.3	0.00	0.00	116.10	117.10	
VSDISVLAK	8.84	1	2	0	(1	1		
VSDISVLAK	52.38	1	2	5.175		nactad	ronorto	r intons	eitide cla	nea hv 1	17 10 [\mathbf{a}
LFFYNNK	52.02	1	2	0 🔺		pecieu	reporte				17.101	Ja
ANVSIPNTVK	24.72	1	3	0 1 1	Ó	0	7.234	0.00	0.00	0.00	117.10	
ANVSIPNTVK	24.41	1	2	0	0	0	4.129	0.00	0.00	0.00	117.10 🖊	
KWDFATDK	5.07	1	2	0	0	0	9.431	0.00	0.00	0.00	117.10	r
STTQAVDYQGLLK	38.18	1	2	0	0 🔺	0	18.48	0.00	0.00	0.00	117.10	
STTQAVDYQGLLK	30.54	1	3	0	04	0	9.236	0.00	0.00	0.00	117.09	
GTTTFSGTVTQPLK	45.07	1	2	0	0	0	31.26	0.00	0.00	0.00	117.11	L
GTTTFSGTVTQPLK	18.06	1	3	2.209	0	0 🔺	24.27	114.07	0.00	0.00	117.11	
TGGDKWDFATSK	11.92	1	2	0	0	0	13.33	0.00	0.00	0.00	117.10	
TGGDKWDFATSK	22.25	1	3	0	5.13	26.59	537.7	0.00	115.10	116.10	117.10	
LDISSNKVSDISVLAK	49.19	1	3	0	0 🔻	0	28.4	0.00	0.00	0.00	117.10	
EGHTFVGWFDAQTGGTK	27.47	1	3	0	0	2.104	7.104	0.00	0.00	116.12	117.10	
EVEAGNLLTEPAKPVK	34.6	1	3	0	0		23.28	0.00	0.00	0.00	117.10	
STTQAVDYQGLLKEPK	50.56	1	3	0	Π	7 2/3	97.09	0.00	0.00	116.13	117.10	
ITQLGLNDQAWTNAPVNYK	51.47	1	2	Llnovn	ootod r	oportor	intoncit		0.00	0.00	117.10	
TNVTDTVSQTDLDQVTTLQADR	99.37	1	3	Ollexh	ected n	eponer	intensit		0.00	0.00	117.11	
TNVTDTVSQTDLDQVTTLQADR	95.1	1	2	U	U	0.12	30.00	0.00	0.00	116.12	117.11	
NLTYLTLYFNNISDISPVSSLTK	57.98	1	3	0	1.104	0	8.095	0.00	115.10	0.00	117.10	
SIDGVEYLNNLTQINFSNNQLTDITPLK	82.99	1	3	0	0	8.225	103.5	0.00	0.00	116.11	117.10	
SIDGVEYLNNLTQINFSNNQLTDITPLK	29.02	1	4	0	0	0	0	0.00	0.00	0.00	0.00	
SIDGVEYLNNLTQINFSNNQLTDITPLK	32.01	1	3	0	1.104	0	57.12	0.00	115.06	0.00	117.11	
SIDGVEYLNNLTQINFSNNQLTDITPLK	31.74	1	3	0	0	0	8.113	0.00	0.00	0.00	117.11	
GTLASLTNLTDLDLANNQISNLAPLSGLT	58.15	1	3	0	0	0	0	0.00	0.00	0.00	0.00	
GILASLINLTDLDLANNQISNLAPLSGLT	30.28	1	4	0	0	0	7.621	0.00	0.00	0.00	117.11	
GTLASLTNLTDLDLANNQISNLAPLSGLT	91.9	1	3	0	0	4.172	56.67	0.00	0.00	116.11	117.11	
GILASLINLTDLDLANNQISNLAPLSGLT	20.11	1	4	0	0	0	2.104	0.00	0.00	0.00	117.10	
VSSLANLTNINWLSAGHNQISDLTPLAN	25.69	1	4	0	0	0	3.156	0.00	0.00	0.00	117.10	



Dynamic range of iTRAQ

A kinase fraction was splited in 4 equal ratios, labeled individually with iTRAQ reagents (114, 115, 116, 117), mixed in variable ratios and were analyzed by LC-MS/MS

Expected ratios:

114	115	116	117
1	1	1	1
1	2	1	2
0	0	4	1
16	1	1	1

Found ratios (sum of 338 peptides):

114	115	116	117
1	0.96	1.03	0.95
1	1.79	1.11	1.82
0.005	0.25	3.47	1
17.8	2.12	1.42	1



Dynamic range of iTRAQ

Observed ratios were caused predominantly by By-products of the iTRAQ reagents:

Reagent	% of -2	% of -1	% of +1	% of +2
iTRAQ™114			5.9	0.2
iTRAQ™115		2.0	5.6	0.1
iTRAQ™116	0.0	3.0	4.5	
iTRAQ™117	0.1	4.0		

By-product certification taken from a typical product sheet (Applied Biosystems)



Specificity of the MS/MS analyses







Specificity of the MS/MS analyses



Monoisotopic mass of neutral peptide (Mr): 1509.76 Fixed modifications: iTRAQ (K),iTRAQ (N-term) Ions Score: 45 Matches (Bold Red): 13/82 fragment ions using 26 most intense peaks

#	b	b++	Ъ ⁰	b ⁰⁺⁺	Seq.	у	y++	y*	y*++	y ⁰	y 0 ++	#
1	292.18	146.59			F							10
2	407.21	204.11	389.19	195.10	D	1219.60	610.30	1202.57	601.79	1201.59	601.30	9
3	538.25	269.63	520.24	260.62	\mathbf{M}	1104.57	552.79	1087.55	544.28	1086.56	543.79	8
4	667.29	334.15	649.28	325.14	E	973.53	487.27	956.51	478.76	955.52	478.27	7
5	780.37	390.69	762.36	381.68	L	844.49	422.75	827.46	414.24	826.48	413.74	6
6	895.40	448.20	877.39	439.20	D	731.41	366.21	714.38	357.69	713.40	357.20	5
7	1010.43	505.72	992.42	496.71	D	616.38	308.69	599.35	300.18	598.37	299.69	4
8	1123.51	562.26	1105.50	553.25	L	501.35	251.18	484.33	242.67			3
9	1220.56	610.79	1202.55	601.78	P	388.27	194.64	371.24	186.12			2
10					K	291.22	146.11	274.19	137.60			1

Fragment ion masses that can be predicted based on the peptide sequence. Experimentally ob-

served masses are assigned in bold red







Acknowledgments





Dr. Josef Wissing Kinome Analysis



Dr. Guido Dieterich Bioinformatics Prof. Jürgen Wehland, and the Department of Cell Biology



Department of Structural Biology Dr. Manfred Nimtz MS-facility

Prof. Klawonn, FH Wolfenbüttel Interpretation of Peptide Fragmentation pattern

Dr. Hendrik Daub, MPI Munich

Kinome mapping



InIB / HGF signaling

Tobias Reinl



Roman Fischer

Phosphorylation site analysis InIA / E-cadherin signaling